Please assess the completion status of the following clinical trial:

Trial Title: Efficacy and Safety of Olokizumab With Rheumatoid Arthritis With Previously Failed to Anti-tumor Necrosis Factor (Anti-TNF) Therapy

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 6.0

Eligibility Criteria:
Inclusion Criteria:~* Have a diagnosis of adult-onset RA of at least 6 months' (24 weeks) duration as defined by the 1987 ACR classification criteria or a score of ≥6 as defined by the ACR/European League Against Rheumatism Classification and Diagnostic Criteria for RA~* Must have moderately to severely active RA disease as defined by ≥6 tender joints (68-joint count) at Screening and Baseline, ≥6 swollen joints (66-joint count) at Screening and Baseline, CRP ≥1.2 times the upper limit of normal (ULN) or ESR \>28mm/hour~* Must be on an MTX dose of 6 to 16mg/week in Japan or 7.5 to 20mg/week in Korea and Taiwan, which has been stable for at least 6 weeks prior to Screening with a stable route of administration~* Must have had intolerance or inadequate response to treatment with 1 or more TNF-blocker therapies within 2 years of Screening~* Female subjects must be either postmenopausal for at least 1 year, surgically incapable of childbearing, or effectively practicing 2 acceptable methods of contraception~Exclusion Criteria:~* Have a diagnosis of any other inflammatory arthritis~* Female subjects who are breast-feeding, pregnant, or plan to become pregnant during the study or within 24 weeks~* Disease modifying antirheumatic drug (DMARDs) other than methotrexate (MTX)~* Subjects with known concurrent acute or chronic viral hepatitis B or C infection~* Subject has known tuberculosis (TB) disease, high risk of acquiring TB infection, or latent TB infection~* Subjects with known history of or current clinically active infection~* Subjects at high risk of infection~* Subjects with known human immunodeficiency virus (HIV) or human T cell lymphotropic virus type 1 (HTLV 1) infection~* Have received vaccinations within 8 weeks prior to Screening or plan to receive vaccines during the study (with the exception of injectable influenza and pneumococcal vaccinations which are permitted)~* Concurrent malignancy or a history of malignancy (with the exception of successfully treated carcinoma of the cervix more than 5 years prior to Screening or no more than 2 successfully treated basal cell carcinomas within 2 years prior to Screening

- Gender: ALL
- Minimum Age: 20 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Placebo every 2 weeks (Type: PLACEBO_COMPARATOR): Injections administered at week 0, 2, 4, 6, 8 and 10
- Olokizumab 60 mg every 2 weeks (Type: EXPERIMENTAL): Olokizumab 60 mg injections administered at week 0, 2, 4, 6, 8 and 10
- Olokizumab 60 mg every 4 weeks (Type: EXPERIMENTAL): Olokizumab 60 mg injection administered at week 0, 4, and 8 and Placebo injection administered at week 2, 6, and 10
- Olokizumab 120 mg every 2 weeks (Type: EXPERIMENTAL): Olokizumab 120 mg injections administered at week 0, 2, 4, 6, 8 and 10
- Olokizumab 120 mg every 4 weeks (Type: EXPERIMENTAL): Olokizumab 120 mg injections administered at week 0, 4 and 8 and Placebo injections at week 2, 6 and 10
- Olokizumab 240 mg very 4 weeks (Type: EXPERIMENTAL): Olokizumab 240 mg injections administered at week 0, 4 and 8 and Placebo injections at week 2, 6 and 10

Based on this trial design, predict the completion outcome and termination type (if applicable).